Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04452513 · ClinicalTrials.gov registry record
A Prospective Clinical Study of Phenylketonuria (PKU)
A clinical trial, sponsored by BioMarin Pharmaceutical.
- Completed
- Registry status
- 32
- Enrollment target
NCT04452513: Completed study, sponsored by BioMarin Pharmaceutical.
NCT04452513 is a clinical trial that has completed, run by BioMarin Pharmaceutical. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04452513 has completed, sponsored by BioMarin Pharmaceutical.
- COMPLETED
- Registry status
- 32 participants
- Enrollment target
Study Summary
This is a study for adults and children ≥ 14 years old who have Phenylketonuria (PKU) with uncontrolled plasma Phe levels. No clinical intervention or study drug is provided by BioMarin in this study.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2019-10-11 |
| Est. Completion | 2022-06-02 |
What the finished NCT04452513 record still lists
NCT04452513 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 32 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04452513 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04452513 about?
NCT04452513 is a clinical study titled "A Prospective Clinical Study of Phenylketonuria (PKU)". This is a study for adults and children ≥ 14 years old who have Phenylketonuria (PKU) with uncontrolled plasma Phe levels. No clinical intervention or study drug is provided by BioMarin in this study.
What is the current status of trial NCT04452513?
This trial is currently completed. The enrollment target is 32 participants. The study started on 2019-10-11. Estimated completion is 2022-06-02.
Who is sponsoring clinical trial NCT04452513?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI